Asian Pacific Journal of Cancer Prevention

  • 제13권5호
  • /
  • Pages.1881-1886
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Breast Cancer Molecular Subtypes and Associations with Clinicopathological Characteristics in Iranian Women, 2002-2011

  • Kadivar, Maryam (Department of Pathology, Tehran University of Medical Sciences) ;
  • Mafi, Negar (Department of Pathology, Tehran University of Medical Sciences) ;
  • Joulaee, Azadeh (Department of Surgery, Shahid Beheshti University of Medical Sciences) ;
  • Shamshiri, Ahmad (Department of Epidemiology, Tehran University of Medical Sciences) ;
  • Hosseini, Niloufar (Department of Pathology, Tehran University of Medical Sciences)
  • 발행 : 2012.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Breast cancer is a heterogeneous disease that is affected by ethnicity of patients. According to hormone receptor status and gene expression profiling, breast cancers are classified into four molecular subtypes, each showing distinct clinical behavior. Lack of sufficient data on molecular subtypes of breast cancer in Iran, prompted us to investigate the prevalence and the clinicopathological features of each subtype among Iranian women. A total of 428 women diagnosed with breast cancer from 2002 to 2011 were included and categorized into four molecular subtypes using immunohistochemistry. Prevalence of each subtype and its association with patients' demographics and tumor characteristics, such as size, grade, lymph-node involvement and vascular invasion, were investigated using Chi-square, analysis of variance and multivariate logistic regression. Luminal A was the most common molecular subtype (63.8%) followed by Luminal B (8.4%), basal-like (15.9%) and HER-2 (11.9%). Basal-like and HER-2 subtypes were mostly of higher grades while luminal A tumors were more of grade 1 (P<0.001). Vascular invasion was more prevalent in HER-2 subtype, and HER-2 positive tumors were significantly associated with vascular invasion (P=0.013). Using muti-variate analysis, tumor size greater than 5 cm and vascular invasion were significant predictors of 3 or more nodal metastases. Breast cancer was most commonly diagnosed in women around 50 years of age and the majority of patients had lymph node metastasis at the time of diagnosis. This points to the necessity for devising an efficient screening program for breast cancer in Iran. Further, prospective surveys are suggested to evaluate prognosis of different subtypes in Iranian patients.

키워드

참고문헌

  1. Al Tamimi DM ,Shawarby MA, Ahmed A, Hassan AK ,AlOdaini AA (2010). Protein expression profile and prevalence pattern of the molecular classes of breast cancer - a Saudi population based study. BMC Cancer, 10, 223.
  2. American Cancer Society (2011). Global Cancer Facts & Figures 2nd Edition. Atlanta.
  3. Anders C, Carey LA (2008). Understanding and treating triplenegative breast cancer. Oncology, 22, 1233-9.
  4. Ben Abdelkrim S, Trabelsi A, Missaoui N, et al (2010). Distribution of molecular breast cancer subtypes among Tunisian women and correlation with histopathological parameters: A study of 194 patients. Pathol Res Pract, 206, 772-5. https://doi.org/10.1016/j.prp.2010.07.012
  5. Bhargava R, Striebel J, Beriwal S, et al (2009). Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J clin Exp Pathol, 2, 444-55.
  6. Blackman DJ, Masi CM (2006). Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes?. J Clin Oncol, 24, 2170-8 https://doi.org/10.1200/JCO.2005.05.4734
  7. Brenton JD, Carey LA, Ahmed AA, Caldas C (2005). Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol, 23, 7350-60. https://doi.org/10.1200/JCO.2005.03.3845
  8. Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes and survival in the Carolina breast cancer study. JAMA, 295, 2492-502. https://doi.org/10.1001/jama.295.21.2492
  9. Crabb SJ, Cheang MC, Leung S, et al (2008). Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer, 8, 249-56. https://doi.org/10.3816/CBC.2008.n.028
  10. de Azambuja E, Cardoso F, de Castro G Jr, et al (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer, 96, 1504-13. https://doi.org/10.1038/sj.bjc.6603756
  11. Del Casar JM, Martín A, García C, et al (2008). Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis. Eur J Obstet Gynecol Reprod Biol, 141, 147-52. https://doi.org/10.1016/j.ejogrb.2008.07.021
  12. Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M (1996). Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res, 2, 147-54.
  13. Harirchi I, Kolahdoozan S, Karbakhsh M, et al (2011). Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncol, 22, 93-7. https://doi.org/10.1093/annonc/mdq303
  14. Huber KE, Carey LA, Wazer DE (2009). Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol, 19, 204-10. https://doi.org/10.1016/j.semradonc.2009.05.004
  15. Huo D, Ikpatt F, Khramtsov A, et al (2009). Population differences in breast cancer: survey indigenous african women reveals over-representation of triple-negative breast cancer. J Clin Oncol, 27, 4515-21. https://doi.org/10.1200/JCO.2008.19.6873
  16. Ihemelandu CU, Leffall LD Jr, Dewitty RL,et al (2007). Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res, 143, 109-18. https://doi.org/10.1016/j.jss.2007.03.085
  17. Iranian Annual of National Cancer Registration Report (2008-2009). Islamic Republic of Iran, Ministry of health and medical education, Center for disease control & prevention, non-communicable diseases unit, cancer office.
  18. Keshgegian AA, Cnaan A (1995). Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol, 104, 42-9. https://doi.org/10.1093/ajcp/104.1.42
  19. Kim MJ, Ro JY, Ahn SH, et al (2006). Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and HER2/neu-over expressing phenotypes. Hum Pathol , 37, 1217-26. https://doi.org/10.1016/j.humpath.2006.04.015
  20. Ma CX, Sanchez CG, Ellis MJ (2009). Predicting endocrine therapy responsiveness in breast cancer. Oncology, 23, 133-42.
  21. Miron L, Marinca A, Marinca M, Miron I (2008). Triple-negative breast cancer-towards a new entity. Rev Med Chir Soc Med Nat Iasi, 112, 51-8.
  22. Mousavi SM, Montazeri A, Mohagheghi MA, et al (2007). Breast cancer in Iran: an epidemiological review. Breast J, 13, 383-91. https://doi.org/10.1111/j.1524-4741.2007.00446.x
  23. Munoz M, Fernández-Acenero MJ, Martín S, Schneider J (2009). Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch Gynecol Obstet, 280, 43-8. https://doi.org/10.1007/s00404-008-0867-1
  24. Nguyen PL, Taghian AG, Katz MS, et al (2008). Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast conserving therapy. J Clin Oncol, 26, 2373-8. https://doi.org/10.1200/JCO.2007.14.4287
  25. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF (2006). Molecular classification of breast cancer: limitations and potential. Oncologist, 11, 868-77. https://doi.org/10.1634/theoncologist.11-8-868
  26. Salhia B, Tapia C, Ishak EA, et al (2011). Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Women's Health, 11, 44. https://doi.org/10.1186/1472-6874-11-44
  27. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82. https://doi.org/10.1126/science.3798106
  28. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74. https://doi.org/10.1073/pnas.191367098
  29. Spitale A, Mazzola P, Soldini D, Mazzucchelli L Bordoni A (2009). Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the south of Switzerland. Ann Oncol, 20, 628-35. https://doi.org/10.1093/annonc/mdn675
  30. Tian XS, Cong MH, Zhou WH, et al (2008). Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie, 31, 610-4. https://doi.org/10.1159/000162288
  31. Trihia H, Murray S, Price K, et al (2003). Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors - a surrogate marker? Cancer, 97, 1321-3. https://doi.org/10.1002/cncr.11188
  32. Wiechmann L, Sampson M, Stempel M, et al (2009). Presenting features of breast cancer differ by molecular subtype (2009). Ann Surg Oncol, 16, 2705-10. https://doi.org/10.1245/s10434-009-0606-2
  33. Yang XR, Sherman ME, Rimm DL, et al (2007). Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev, 16, 439-43. https://doi.org/10.1158/1055-9965.EPI-06-0806
  34. Zaha DC, Lazar E, Lazureanu C (2010). Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. Rom J Morphol Embryol, 51, 85-9.
  35. Zhao J, Liu H, Wang M, et al (2009). Characteristics and prognosis for molecular breast cancer subtypes in chinese women. J Surg Oncol, 100, 89-94. https://doi.org/10.1002/jso.21307

피인용 문헌

  1. Disease Free Survival among Molecular Subtypes of Early Stage Breast Cancer between 2001 and 2010 in Iran vol.14, pp.10, 2013, https://doi.org/10.7314/APJCP.2013.14.10.5811
  2. A meta-analysis of the association of glutathione S-transferase P1 gene polymorphism with the susceptibility of breast cancer vol.40, pp.4, 2013, https://doi.org/10.1007/s11033-012-2396-z
  3. Breast Cancer Recurrence According to Molecular Subtype vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5539
  4. Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6109
  5. An 18-Gene Signature for Vascular Invasion Is Associated with Aggressive Features and Reduced Survival in Breast Cancer vol.9, pp.6, 2014, https://doi.org/10.1371/journal.pone.0098787
  6. Immunohistochemical characterization of the molecular subtypes of invasive breast carcinoma in a series of Egyptian female patients with clinicopathologic correlation vol.37, pp.1, 2017, https://doi.org/10.1097/01.XEJ.0000515971.96677.e7
  7. Awareness and current knowledge of breast cancer vol.50, pp.1, 2017, https://doi.org/10.1186/s40659-017-0140-9